Sage Therapeutics (SAGE) Competitors $9.20 +0.12 (+1.27%) Closing price 07/3/2025 02:52 PM EasternExtended Trading$9.20 0.00 (0.00%) As of 07/3/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAGE vs. BHC, GMTX, APLS, ARWR, TWST, VCEL, KNSA, NAMS, DNLI, and RXRXShould you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Vericel (VCEL), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Sage Therapeutics vs. Its Competitors Bausch Health Cos Gemini Therapeutics Apellis Pharmaceuticals Arrowhead Pharmaceuticals Twist Bioscience Vericel Kiniksa Pharmaceuticals International NewAmsterdam Pharma Denali Therapeutics Recursion Pharmaceuticals Bausch Health Cos (NYSE:BHC) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership. Is BHC or SAGE more profitable? Bausch Health Cos has a net margin of -0.41% compared to Sage Therapeutics' net margin of -747.63%. Sage Therapeutics' return on equity of -68.99% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets Bausch Health Cos-0.41% -540.45% 5.26% Sage Therapeutics -747.63%-68.99%-60.67% Do institutionals & insiders believe in BHC or SAGE? 78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are owned by institutional investors. 8.1% of Bausch Health Cos shares are owned by company insiders. Comparatively, 5.5% of Sage Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, BHC or SAGE? Bausch Health Cos has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Does the media favor BHC or SAGE? In the previous week, Sage Therapeutics had 4 more articles in the media than Bausch Health Cos. MarketBeat recorded 6 mentions for Sage Therapeutics and 2 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.48 beat Sage Therapeutics' score of 0.18 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sage Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate BHC or SAGE? Bausch Health Cos presently has a consensus price target of $7.42, indicating a potential upside of 6.73%. Sage Therapeutics has a consensus price target of $8.93, indicating a potential downside of 2.85%. Given Bausch Health Cos' higher probable upside, analysts plainly believe Bausch Health Cos is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Cos 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86Sage Therapeutics 1 Sell rating(s) 15 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger valuation & earnings, BHC or SAGE? Bausch Health Cos has higher revenue and earnings than Sage Therapeutics. Bausch Health Cos is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch Health Cos$9.63B0.27-$46M-$0.11-63.17Sage Therapeutics$41.24M13.96-$400.67M-$5.80-1.59 SummaryBausch Health Cos beats Sage Therapeutics on 9 of the 16 factors compared between the two stocks. Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAGE vs. The Competition Export to ExcelMetricSage TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$576.11M$2.92B$5.55B$9.05BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-1.5921.5627.6120.23Price / Sales13.96278.31417.23118.52Price / CashN/A42.7336.8958.10Price / Book1.217.518.035.67Net Income-$400.67M-$55.14M$3.18B$249.21M7 Day Performance0.49%4.61%2.93%3.28%1 Month Performance35.62%4.72%3.75%5.55%1 Year Performance-14.70%5.92%35.20%21.09% Sage Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAGESage Therapeutics3.2294 of 5 stars$9.20+1.3%$8.93-2.8%-13.4%$576.11M$41.24M-1.59690High Trading VolumeBHCBausch Health Cos3.1195 of 5 stars$6.11-1.1%$7.42+21.4%-2.8%$2.26B$9.73B-55.5520,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+23.2%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.428 of 5 stars$17.62-0.4%$40.05+127.3%-49.2%$2.21B$775.84M-9.84770Trending NewsAnalyst ForecastAnalyst RevisionARWRArrowhead Pharmaceuticals3.9458 of 5 stars$15.51+1.2%$43.71+181.8%-33.1%$2.14B$3.55M-11.08400TWSTTwist Bioscience4.4703 of 5 stars$35.33+2.0%$50.40+42.7%-20.6%$2.12B$347.68M-10.87990VCELVericel2.8497 of 5 stars$41.80-0.5%$61.14+46.3%-7.0%$2.10B$237.22M1,393.80300News CoveragePositive NewsKNSAKiniksa Pharmaceuticals International3.2779 of 5 stars$28.72+1.0%$38.80+35.1%+45.8%$2.10B$423.24M-114.88220NAMSNewAmsterdam Pharma2.2894 of 5 stars$18.21+1.4%$42.89+135.5%-0.8%$2.04B$45.56M-9.694Analyst UpgradeDNLIDenali Therapeutics4.6377 of 5 stars$13.62-1.9%$33.71+147.5%-31.0%$1.98B$330.53M-5.10430Positive NewsRXRXRecursion Pharmaceuticals1.9297 of 5 stars$4.83-4.0%$7.00+44.9%-28.4%$1.96B$58.84M-2.73400Analyst Forecast Related Companies and Tools Related Companies Bausch Health Cos Competitors Gemini Therapeutics Competitors Apellis Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Twist Bioscience Competitors Vericel Competitors Kiniksa Pharmaceuticals International Competitors NewAmsterdam Pharma Competitors Denali Therapeutics Competitors Recursion Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAGE) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SAGE Stock Alerts